Compare ELMT & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELMT | RGNX |
|---|---|---|
| Founded | 1929 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 474.9M | 487.2M |
| IPO Year | 2026 | 2015 |
| Metric | ELMT | RGNX |
|---|---|---|
| Price | $19.69 | $7.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $29.00 | $21.40 |
| AVG Volume (30 Days) | 472.3K | ★ 1.1M |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.08 |
| EPS | ★ 0.10 | N/A |
| Revenue | N/A | ★ $10,393,000.00 |
| Revenue This Year | $34.89 | N/A |
| Revenue Next Year | $29.22 | $24.01 |
| P/E Ratio | $194.45 | ★ N/A |
| Revenue Growth | N/A | ★ 126.48 |
| 52 Week Low | $12.49 | $5.46 |
| 52 Week High | $25.46 | $16.19 |
| Indicator | ELMT | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 46.04 | 44.73 |
| Support Level | $17.53 | $6.79 |
| Resistance Level | $21.38 | $7.32 |
| Average True Range (ATR) | 2.19 | 0.59 |
| MACD | -0.20 | -0.03 |
| Stochastic Oscillator | 31.09 | 15.40 |
The Elmet Group Co provides precision-engineered components and high-energy systems for the Aerospace, Defense and Government, Industrial, Medical, Semiconductor and Electronics, and Energy industries. The company is organized into two business divisions, Critical Materials Components and Engineered Microwave Products, offering a platform with expertise across interconnected markets. The company operates an integrated engineering-to-production system, covering custom design, development, and processing across Critical Materials and High-Power Microwave. Its Engineered Microwave capabilities helps to deliver tailored microwave energy solutions, while its Critical Materials expertise allows to design reliable solutions for some of the demanding environments in the world.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.